IDH2 and acute myeloid leukemia: With the encouraging data incorporating venetoclax, FLT3 inhibitors, IDH inhibitors, and monoclonal antibodies (GO, novel CD33 monoclonal antibodies), combined modality strategies involving targeted agents and chemotherapy are becoming a reality in the management of all younger and older patients with AML.